Alzheimer’s drug targeting soluble amyloid falls short trial

The current armamentarium against Alzheimer’s disease consists only of drugs that provide symptomatic relief, and the benefits are modest at best. Medications that can stop, slow, or prevent the underlying pathophysiology of Alzheimer’s disease are desperately needed.

Several companies have developed drugs that act against β-amyloid plaques, which are thought to play a central role in causing Alzheimer’s, only to see them falter in late-stage clinical trials. In fact, some have questioned whether β-amyloid plaque is the right target for treatment drugs. So it caused quite a stir earlier this year when Biogen presented encouraging data from an interim analysis of a phase 1b trial of aducanumab, a high-affinity antibody against β-amyloid, at the International Conference on Alzheimer’s and Parkinson’s Diseases in Nice, France. Based on these results, Biogen plans to start a phase 3 trial of aducanumab later this year.

The multicenter, randomized, double-blind, placebo-controlled study involved people with prodromal or mild Alzheimer’s who were, on average, between 70 and 74 years of age and were confirmed to have β-amyloid plaques using a florbetapir positron emission tomography (PET) scan. One hundred sixty-six subjects were randomized into 1 of 5 treatment groups (placebo, 1 mg/kg, 3 mg/kg, 6 mg/kg, and 10 mg/kg of aducanumab) for 52 weeks.

Reduction in amyloid plaque, as measured by the Standard Uptake Value Ratio (SUVR) of florbetapir, was seen at 26 weeks with further reductions at 54 weeks. With the mean baseline SUVR value between 1.4 and 1.5 among all the study arms, the mean composite SUVR in the highest dose arm was about 1.175 by Week 54 (in healthy people, SUVR is <1.13). Importantly, in addition to the significant reduction in amyloid plaque measurements, aducanumab was also associated with a slower rate of cognitive decline, as measured by the Mini-Mental State Examination (MMSE) and Clinical Dementia Rating Scale-sum of boxes (CDR-sb) scores.

Preliminary data show aducanumab reduced amyloid plaques, as measured by SUVR

Change in SUVR

*Denotes statistical significance

Sources: Sevigny J et al., Neurodegenerative Diseases, March 2015; Sevigny J et al., 12th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, March 2015; Biogen news release, March 20, 2015

The phase 3 trial has been designed to include more than 1,000 patients. The failures of other β-amyloid drugs are recent enough to guard against unbridled optimism. But if aducanumab were to make it to market, it would be a major advance to have a disease-modifying drug for Alzheimer’s disease.

Krishna Rutvij Patel, PharmD, is a clinical services manager at MediMedia Managed Markets. She is an adjunct faculty member of the Philadelphia College of Pharmacy and a 2012 graduate of the school.

MC TV

Explore the complexities of the biosimilars’ landscape, such as naming, interchangeability and substitution, differences in the manufacturing processes, as well as the approval pathways & FDA guidelines for biologics, including draft guidance on biosimilars.

USA-BIO-106112

5B

The problem stems from the inability of health plans and out-of-network hospital specialty providers to agree on a proper fee, so consumers end up being billed the balance. The issue has gotten national attention and legislators vow to come up with a solution.

Continue reading…

6

Democratic frontrunner Hillary Clinton is likely to paint the ACA as a symbol of success that just needs a bit of fine-tuning. GOP candidates want to repeal and replace it, but the eventual nominee with be asked: Replace it with what, exactly?

Continue reading…

7

Quality tools are not some panacea. The fact is that few patients use the proprietary quality and price transparency apps that health plans provide. Are they not useful? Do people not care? Are health plans not to be trusted? Answer: all of the above.

Continue reading…

8

Health insurers are a prime target because of the richness of the information they hold. Payers need to increase their investment in people and processes to try to fend off data breaches. The greatest risk might come from interaction with vulnerable third-party vendors.

Continue reading…

9

Everyone in health care recognizes that early detection comes at a cost: It can lead to unnecessary treatment and spending and, in some cases, real harm to patients because of the risks and side effects of treatment. This is a particularly vexing problem when it comes to cancer screening.

Continue reading…

10

The foundation for the Medicare Access and CHIP Reauthorization Act (MACRA)—scheduled to go into effect in 2019—will start to be laid in 2016. The law affects physicians receiving Medicare payments, but not all of them will be happy with the changes.

Continue reading…

11

Health plans can’t keep up with orders from physicians for new complex molecular diagnostic tests that clinical labs develop and promote as the next best technology to improve patient care. The issue is proper vetting, and the debate promises to become more heated.

Continue reading…

NEWS & COMMENTARY
Finally, a success story for the struggling health insurance exchange (HIE) effort. Researchers were able to accurately predict health care utilization in Maine for more than a million patients for six months using only demographic and electronic medical records (EMRs) data from the previous year.

Continue reading…


Our most popular topics on Managedcaremag.com